CN114703106A - 益生菌GforU-12及应用 - Google Patents
益生菌GforU-12及应用 Download PDFInfo
- Publication number
- CN114703106A CN114703106A CN202210484938.XA CN202210484938A CN114703106A CN 114703106 A CN114703106 A CN 114703106A CN 202210484938 A CN202210484938 A CN 202210484938A CN 114703106 A CN114703106 A CN 114703106A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- gforu
- lysate
- metabolite
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 16
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 62
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 62
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 62
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 14
- 206010000496 acne Diseases 0.000 claims abstract description 14
- 208000035985 Body Odor Diseases 0.000 claims abstract description 11
- 206010055000 Bromhidrosis Diseases 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 43
- 230000001580 bacterial effect Effects 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 30
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 24
- 239000006166 lysate Substances 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000002207 metabolite Substances 0.000 claims description 19
- 241000186612 Lactobacillus sakei Species 0.000 claims description 16
- 241000606768 Haemophilus influenzae Species 0.000 claims description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 13
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 13
- 230000000813 microbial effect Effects 0.000 claims description 13
- 230000008439 repair process Effects 0.000 claims description 13
- 241000186427 Cutibacterium acnes Species 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 12
- 229940055019 propionibacterium acne Drugs 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 6
- 230000008591 skin barrier function Effects 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 4
- 102100026326 Putative transcription factor Ovo-like 1 Human genes 0.000 claims description 4
- 101150016206 Trpv1 gene Proteins 0.000 claims description 4
- 230000002222 downregulating effect Effects 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 3
- 241000192087 Staphylococcus hominis Species 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 210000001339 epidermal cell Anatomy 0.000 claims description 3
- 102000003566 TRPV1 Human genes 0.000 claims description 2
- 108700026241 pX Genes Proteins 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 3
- 101150063233 FLG gene Proteins 0.000 claims 1
- 101150028412 GBA gene Proteins 0.000 claims 1
- 101150027725 IVL gene Proteins 0.000 claims 1
- 101150012407 OVOL1 gene Proteins 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 8
- 230000004888 barrier function Effects 0.000 abstract description 5
- 238000004321 preservation Methods 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000006228 supernatant Substances 0.000 description 30
- 238000012258 culturing Methods 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 239000001963 growth medium Substances 0.000 description 17
- 244000052616 bacterial pathogen Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 238000009630 liquid culture Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- 241000191963 Staphylococcus epidermidis Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 244000005714 skin microbiome Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000917159 Homo sapiens Filaggrin Proteins 0.000 description 3
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 3
- 101001121371 Homo sapiens Putative transcription factor Ovo-like 1 Proteins 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 102100023913 Involucrin Human genes 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 2
- 244000141698 Prunus lannesiana Species 0.000 description 2
- 235000014001 Prunus serrulata Nutrition 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 101150116870 LORICRIN gene Proteins 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
Abstract
本发明涉及微生物技术领域,特别涉及益生菌GforU‑12及应用。本发明提供了一株植物乳杆菌GforU‑12及应用,保藏编号为CCTCC NO:M 2022108。此菌株GforU‑12具有修护屏障、治疗皮肤炎症、鼻窦炎、痤疮和臭汗症功能,可用于食品、药品、化妆品等。
Description
技术领域
本发明涉及微生物技术领域,特别涉及益生菌GforU-12及应用。
背景技术
皮肤作为人体最大的器官生活着广泛的微生物,皮肤构成了陷入部、经特化的间隙等多样形态的栖息地,帮助分布广泛的微生物能够生存。微生物与作为宿主的人构成了共生关系,皮肤微生物群在宿主中发挥重要而有用的功能,不仅因为它有能力抵抗皮肤病原体的粘附和发展,还因为它有能力与免疫系统对话和相互作用。微生物和皮肤环境之间的平衡一旦被打破,本来无害的微生物将由健康状态变为致病状态,就会引起各种皮肤疾病;反之,皮肤疾病也会导致皮肤微生物结构异常和菌群失调,所以很多皮肤问题都与皮肤微生态失衡有着密切关系。
益生菌在维持宿主机体稳态,激活免疫系统、维持机体免疫平衡等方面具有重要作用,研究发现益生菌能通过调节巨噬细胞的吞噬能力以及细胞因子的释放来控制全身免疫状态,从而预防和治疗各种炎症疾病。益生菌外用可以使皮肤表面的微生物菌群达到平衡,促进皮肤屏障的修护。
鼻窦炎是耳鼻咽喉科学中的常见疾病,主要由呼吸道变态反应、鼻-鼻窦粘膜清洁功能障碍、呼吸道微生物感染、鼻局部解剖结构异常等因素引发。研究表明流感嗜血杆菌(Haemophilus influenzae)和铜绿假单胞菌(Pseudomonas aeruginosa)是鼻窦炎的重要病原菌,而清酒乳杆菌(Lactobacillus sakei)对于维持鼻腔正常功能有积极作用。因此,降低流感嗜血杆菌/清酒乳酸菌和铜绿假单胞菌/清酒乳酸菌的菌群比例,有助于鼻窦炎的治疗。
痤疮是一种常见的慢性炎症性皮肤疾病,主要与皮脂分泌过多、毛囊皮脂腺导管堵塞、细菌感染和炎症反应等因素密切相关。研究表明,痤疮丙酸杆菌(Propionibacteriumacne)被认为引发痤疮的主要病原菌,它可以诱导和活化痤疮炎症的起始环节,并将甘油转换为脂肪酸,导致炎症反应;同时产生蛋白酶、透明质酸酶及趋化因子,使毛囊过度角化,形成痤疮。另一方面,皮肤常驻的表皮葡萄球菌(Staphylococcus epidermidis)与痤疮丙酸杆菌能够相互拮抗竞争,增加表皮葡萄球菌的数量能够抑制痤疮丙酸杆菌增殖。因此,降低痤疮丙酸杆菌/表皮葡萄球菌的菌群比例,可以有效缓解痤疮炎症,从而通过调节皮肤微生态平衡来维持皮肤健康。
臭汗症是指汗液中具有特殊臭味的现象,主要包括足臭和腋臭。二者成因机制不尽相同,但都与特定部位菌群的代谢过程密切相关,其中主要涉及葡萄球菌属。研究发现益生菌灭活上清液能够显著降低相关病原菌的生长,可以通过直接接触并抑制病原菌的方式,有效改善臭汗症,发挥除臭功效。
因此,提供能够预防和治疗各种炎症疾病和臭汗症的益生菌具有重要的现实意义。
发明内容
有鉴于此,本发明提供了益生菌GforU-12及应用,具有修护屏障、治疗皮肤炎症、鼻窦炎、痤疮和臭汗症的功效。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物,其保藏编号为CCTCC NO:M 2022108。
在本发明的一些具体实施方案中,上述植物乳杆菌(Lactobacillus plantarum)是活的或死的或经间歇灭菌的,或为裂解物和/或提取物的形式,或为细菌产物的形式或为上清液形式或衍生物形式,所述衍生物形式包括:代谢产物、代谢生物产物、益生素、细胞壁及其成分、胞外多糖,和含有免疫原性成分的化合物,包括:上清液、灭活菌体。
本发明还提供了上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备调节菌群、抗炎和/或抗过敏的产品中的应用。
本发明还提供了上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备促进表皮细胞修复、修复皮肤屏障、皮肤保湿、改善肌肤状况、治疗臭汗症、治疗痤疮和/或治疗鼻窦炎的产品中的应用。
本发明还提供了上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备下调细胞炎症因子表达、降低炎症因子释放、抑制致病菌生长、促进益生菌增殖和/或改变菌群比例的产品中的应用。
本发明还提供了上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备降低细胞一氧化氮生成量,下调细胞IL-6、IL-8、COX-2和/或TRPV1的表达,提升由十二烷基硫酸钠损伤的细胞的存活率,上调FLG、IVL、OVOL1、LOR和/或GBA基因的表达,抑制流感嗜血杆菌生长,抑制铜绿假单胞菌生长,促进清酒乳杆菌增殖,抑制痤疮丙酸杆菌生长,抑制金黄色葡萄球菌生长,抑制人葡萄球菌生长和/或抑制溶血葡萄球菌生长的产品中的应用。
在本发明的一些具体实施方案中,上述植物乳杆菌(Lactobacillus plantarum)能降低流感嗜血杆菌/清酒乳杆菌的比例、降低铜绿假单胞菌/清酒乳杆菌的比例、降低痤疮丙酸杆菌/表皮葡萄球菌的比例。
在本发明的一些具体实施方案中,上述应用所述产品包括微生物制剂、食品、药物或化妆品。
本发明还提供了微生物制剂,具有上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物以及可接受的辅料和/或助剂。
在本发明的一些具体实施方案中,上述微生物制剂还包括酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌和/或放线菌等。
本发明还提供了食品,具有上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物,和/或上述微生物制剂以及可接受的辅料和/或助剂。
本发明还提供了药物,具有上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物,和/或上述微生物制剂以及可接受的辅料和/或助剂。
本发明还提供了化妆品,具有上述植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物,和/或上述微生物制剂以及可接受的辅料和/或助剂。
在本发明的一些具体实施方案中,上述辅料或助剂包括营养强化剂、甜味调节剂、酸度调节剂、等渗调节剂、填充剂、粘合剂、崩解剂、增溶剂、助溶剂、防腐剂、矫味剂、着色剂、助悬剂、润湿剂、乳化剂和/或表面活性剂。
本发明的菌株有如下效果:
本发明从发酵樱菜中分离鉴定的植物乳杆菌GforU-12,兼具修护屏障、治疗皮肤炎症、鼻窦炎、痤疮和臭汗症的功能,在食品、药品、化妆品等领域具有极大的市场潜力。
1、GforU-12经16S rRNA鉴定为植物乳杆菌(Lactobacillus plantarum)。
2、体外细胞实验表明,本发明的植物乳杆菌GforU-12具有降低炎症因子释放的作用,能够降低脂多糖(LPS)诱导小鼠巨噬细胞Raw264.7的一氧化氮(NO)生成量38.78%~39.46%。
3、体外细胞实验表明,本发明的植物乳杆菌GforU-12具有下调金黄色葡萄球菌诱导的HaCaT细胞炎症相关因子IL-6、IL-8、COX-2和TRPV1基因表达的作用,基因表达量下调33%~81%。
4、体外细胞实验表明,本发明的植物乳杆菌GforU-12具有促进表皮细胞修复的作用,GforU-12提升十二烷基硫酸钠(SDS)损伤的HaCaT细胞存活率达107.91%~112.77%。
5、体外细胞实验表明,本发明的植物乳杆菌GforU-12具有上调皮肤屏障修护相关因子丝聚合蛋白基因FLG、外皮蛋白基因IVL、OVO样转录因子1基因OVOL1和兜甲蛋白基因LOR表达的作用,基因表达量上调1.23~1.91倍。
6、体外细胞实验表明,本发明的植物乳杆菌GforU-12具有上调保湿相关基因表皮β-葡糖脑苷脂酶基因GBA的作用,基因表达量上调1.78倍。
7、体外实验表明,本发明的植物乳杆菌GforU-12具有降低流感嗜血杆菌/清酒乳杆菌、铜绿假单胞菌/清酒乳杆菌的比例,从而治疗鼻窦炎的功能。
8、体外实验表明,本发明的植物乳杆菌GforU-12具有降低痤疮丙酸杆菌/表皮葡萄球菌的比例,从而治疗痤疮的功能。
9、体外实验表明,本发明的植物乳杆菌GforU-12具有抑制臭汗症病原菌金黄色葡萄球菌(Staphylococcus aureus)、人葡萄球菌(Staphylococcus hominis)和溶血葡萄球菌(Staphylococcus haemolyticus)生长的作用,抑制率34.68%~40.01%。
生物保藏说明
生物材料:GforU-12,分类命名:植物乳杆菌GforU-12(Lactobacillus plantarumGforU-12),于2022年01月21日保藏于中国典型培养物保藏中心,保藏中心地址为:中国.武汉.武汉大学;保藏编号为CCTCC NO:M 2022108。
本发明中所述GforU-12即为上述保藏编号为CCTCC NO:M 2022108的菌株。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示GforU-12下调HaCaT细胞炎症相关因子的表达;
图2示GforU-12灭活菌体上调修复基因的表达。
具体实施方式
本发明公开了益生菌GforU-12及应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
该菌株革兰氏阳性,显微镜下呈杆状;在MRS平板上生长,可形成表面光滑不透明的圆形菌落,白色,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀,最适生长温度37℃。
本发明所用原料及试剂均可由市场购得。
下面结合实施例,进一步阐述本发明:
实施例1:GforU-12的分离
发酵樱菜中采样。将样品适当处理后于生理盐水中震荡混匀,取上清划线于MRS固体平板,37℃恒温培养24~48h后,挑取白色菌落反复接种筛选,直至得到均匀的单个菌落,命名为GforU-12。
革兰氏染色镜检:菌株GforU-12为革兰氏染色阳性,显微镜下呈杆状;在MRS平板上生长,可形成白色、表面光滑圆润不透明圆形小菌落,边缘整齐;在MRS液体培养基中呈均匀浑浊生长,久置菌体呈白色沉淀。
实施例2:GforU-12的核酸鉴定
1、16s rRNA基因序列分析
挑取单菌落置MRS液体培养基中,37℃培养过夜后,离心收集菌体,按照DNA提取试剂盒步骤进行操作。引物用细菌通用引物27F,1492R,PCR扩增体系为50μL体系,95℃预变性5min;94℃15s,57℃15s,72℃40s,35个循环;72℃延伸10min。
2、结果
PCR产物测序结果与GenBank中已发表的标准序列进行同源性比较(BLASTN)后得出GforU-12菌株为植物乳杆菌(Lactobacillus plantarum)。
实施例3:GforU-12降低Raw264.7细胞NO生成量
1、GforU-12菌液制备
将GforU-12用MRS培养基培养过夜,检测OD600,调整菌液浓度至OD600=0.2,离心后,菌体121℃高压灭菌30min得菌体,离心上清用0.22μm滤膜过滤得上清液。
2、Raw264.7细胞制备
将Raw264.7细胞消化后以2×105cells/孔接种至24孔板,5%二氧化碳培养箱37℃培养过夜。
3、GforU-12添加及LPS刺激
将上清液5%(V/V)、灭活菌体10%(V/V)分不同组加入培养过夜的Raw264.7细胞中,2h后添加0.5mL浓度为0.2μg/mL的LPS溶液,诱导Raw264.7细胞发炎,20h后取细胞培养上清液,按照碧云天NO检测试剂盒所述方法进行标准曲线绘制,计算样品中NO的浓度及抑制率。
4、结果如表1所示:
表1 GforU-12降低Raw264.7细胞NO生成量
结果显示GforU-12具有抗炎作用,能够降低LPS诱导的Raw264.7细胞NO生成量,与LPS对照组相比上清液降低38.78%,灭活菌体降低39.46%。
实施例4:GforU-12下调HaCaT细胞炎性因子的表达
1、GforU-12样品制备
将GforU-12用MRS培养过夜,检测OD600,调整菌液浓度至OD600=0.2,离心后,菌体121℃高压灭菌30min得菌体,离心上清用0.22μm滤膜过滤得上清液。
2、HaCaT细胞制备
将HaCaT细胞消化后以2×105cells/孔接种至24孔板,5%二氧化碳培养箱37℃培养过夜。
3、金黄色葡萄球菌制备及添加
金黄色葡萄球菌接入营养肉汤培养基,37℃摇床培养过夜,用MEM无血清培养基调整菌液浓度至OD600=6,每孔100μl添加入培养过夜的HaCaT细胞中,刺激细胞产生炎症因子,3h后弃去细胞培养基,PBS清洗5次,每孔重新加入1mL的MEM无血清培养基。
4、GforU-12样品添加
将GforU-12上清液以5%加入金黄色葡萄球菌刺激过的HaCaT细胞中,每组3个复孔,培养过夜。
5、qPCR法检测细胞炎症因子mRNA相对表达倍数
将上述细胞弃去培养基后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度,将所有样品RNA总量调整至1μg,用反转录试剂盒、SYBR Green qPCR试剂盒进行RT-PCR及qPCR,以不添加菌株上清液和灭活菌体的处理组为对照,其基因表达量为1,根据公式计算实验组炎症因子相关基因相对表达倍数F。
公式:F=2-ΔΔCT
6、结果:如图1、表2所示:
表2 GforU-12下调炎症因子相关基因的表达
结果显示GforU-12能够下调金黄色葡萄球菌诱导的HaCaT炎性因子IL-6、IL-8、COX-2和TRPV1基因表达量降低。因此,GforU-12具有抗炎作用。
实施例5:GforU-12促进SDS诱导的HaCaT细胞损伤修复实验
1、GforU-12菌液制备
将活化的植物乳杆菌GforU-12菌液以MRS液体培养基培养于37℃培养箱静置培养16~18h,检测并调整OD600=2.0,121℃,30min灭活,离心取沉淀为灭活菌体,上清液经0.22μm滤膜过滤为灭活上清液。
2、促进HaCaT细胞修复实验
接种HaCaT细胞(5×104cells/孔)至96孔板,过夜培养至细胞贴壁。配制50μg/mLSDS,每孔加入100μL,孵育8h,分别加入5%上清液和10%灭活菌体,孵育24h。加入10μL的CCK-8溶液,孵育4h,检测450nm处吸光度A。
细胞存活率=实验组A/对照组A×100%。
3、结果如表3所示:
表3 GforU-12促进SDS诱导的HaCaT细胞损伤修复
GforU-12上清液及灭活菌体均对HaCaT细胞SDS损伤具有修复作用。
实施例6:GforU-12促进HaCaT屏障修护相关基因表达实验
接种人永生化角质形成细胞HaCaT(5×105cells/孔)至6孔板,过夜培养至细胞贴壁。加入菌株灭活菌体10%,分别培养24h后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度,将所有样品RNA总量调整至1μg进行反转录,进行qPCR检测FLG、IVL、OVOL1和LOR基因的表达。以不添加菌株上清液和灭活菌体的处理组为对照,其基因表达量为1,根据公式计算实验组修护相关基因相对表达倍数F。
公式:F=2-ΔΔCT
结果:如图2、表4所示:
表4 GforU-12灭活菌体上调屏障修护相关基因表达
结果显示加入GforU-12具有促进皮肤屏障修护的作用。
实施例7:GforU-12上调HaCaT保湿相关基因表达实验
接种人永生化角质形成细胞HaCaT(5×105cells/孔)至6孔板,过夜培养至细胞贴壁。加入菌株灭活菌体10%,培养24h后,加入裂解液,提取细胞总RNA,检测RNA浓度及纯度,将所有样品RNA总量调整至1μg进行反转录,进行qPCR检测保湿相关基因GBA的表达。以不添加菌株上清液和灭活菌体的处理组为对照,其基因表达量为1,根据公式计算实验组GBA相对表达倍数。
公式:F=2-ΔΔCT
结果如表5所示:
表5 GforU-12灭活菌体上调保湿基因GBA的表达
结果显示加入GforU-12具有促进皮肤保湿的作用。
实施例8:GforU-12改变菌群比例治疗鼻窦炎的作用
1、植物乳杆菌GforU-12菌液制备
将活化的植物乳杆菌GforU-12菌液以MRS液体培养基培养于37℃培养箱静置培养16~18h,检测并调整OD600=2.0,121℃,30min灭活,离心取上清液,0.22μm滤膜过滤,得待测样品。
2、鼻腔菌群菌液制备
培养流感嗜血杆菌ATCC49766:将流感嗜血杆菌冻存菌液于BHI固体培养基四区划线,37℃培养24~48h,挑取单菌落于BHI液体培养基37℃培养18h,测定菌液OD600,并用BHI液体稀释至OD600=0.2。
培养铜绿假单胞菌CGMCC1.1783:将铜绿假单胞菌冻存菌液于BHI固体培养基四区划线,37℃培养24~48h,挑取单菌落于BHI液体培养基37℃培养18h,测定菌液OD600,并用BHI液体稀释至OD600=0.2。
培养清酒乳杆菌ATCC15521:将清酒乳杆菌冻存菌液于MRS固体培养基四区划线,37℃培养24~48h,挑取单菌落于MRS液体培养基37℃培养18h,测定菌液OD600,并用MRS液体稀释至OD600=0.2。
将GforU-12灭活上清液以10%分别加入三种鼻腔菌群菌液中,培养至对数期,分别测定菌液浓度(OD600),以未添加上清液的菌液为对照,计算三种菌液的相对浓度(对照=100%),以流感嗜血杆菌/清酒乳杆菌相对浓度比值和铜绿假单胞菌/清酒乳杆菌相对浓度比值评价对鼻腔菌群生长影响。
3、添加上清液影响鼻腔菌群生长实验
将灭活上清液以10%分别加入三种菌液中,37℃培养3h,以流感嗜血杆菌/清酒乳杆菌、铜绿假单胞菌/清酒乳杆菌相对浓度(OD600)比值评价对鼻腔菌群生长影响。
4、结果如表6、表7所示:
表6 GforU-12对流感嗜血杆菌/清酒乳杆菌比值影响
表7 GforU-12对铜绿假单胞菌/清酒乳杆菌比值影响
结果显示GforU-12对流感嗜血杆菌和铜绿假单胞菌有显著抑制作用,而对清酒乳杆菌有一定促进增殖作用。GforU-12能够明显改变鼻腔菌群比例,从而有效治疗鼻窦炎。
实施例9:GforU-12改变菌群比例治疗痤疮的作用
1、植物乳杆菌GforU-12菌液制备
将活化的植物乳杆菌GforU-12菌液以MRS液体培养基培养于37℃培养箱静置培养16~18h,检测并调整OD600=2.0,121℃,30min灭活,离心取上清液,0.22μm滤膜过滤,得待测样品。
2、皮肤菌群菌液制备
将痤疮丙酸杆菌CGMCC 1.5003和表皮葡萄球菌CGMCC 1.4260分别以BHI培养基37℃培养18h,检测并调整OD600=0.2。
3、添加上清液影响皮肤菌群生长实验
将灭活上清液以10%分别加入两种菌液中,培养至对数期,分别测定两种菌液浓度(OD600),以未添加上清液的菌液为对照,计算两种菌液的相对浓度,以痤疮丙酸杆菌/表皮葡萄球菌相对浓度比值评价对皮肤菌群生长影响。
4、结果如表8所示:
表8 GforU-12对痤疮相关菌群生长影响
结果显示GforU-12对痤疮丙酸杆菌有显著抑制作用,而对表皮葡萄球菌抑制作用则低得多。GforU-12能够明显改变皮肤菌群比例,从而达到治疗痤疮的目的。
实施例10:GforU-12抑制臭汗症病原菌生长实验-菌液浓度变化
1、植物乳杆菌GforU-12菌液制备
将活化的植物乳杆菌GforU-12菌液以MRS液体培养基培养于37℃培养箱静置培养16~18h,检测并调整OD600=2.0,121℃,30min灭活,离心取上清液,0.22μm滤膜过滤,得待测样品。
2、病原菌菌液制备
将3种病原菌:金黄色葡萄球菌CGMCC1.8721、人葡萄球菌CGMCC1.493、溶血葡萄球菌CGMCC 1.540分别以BHI培养基37℃培养18h,检测并调整OD600=0.2。
3、抑制臭汗症病原菌实验
将灭活上清液以10%加入病原菌中,37℃培养2h,以抑制率评价对病原菌生长的抑制作用。
4、结果如表9所示:
表9 GforU-12对臭汗症病原菌抑制率
结果显示GforU-12对金黄色葡萄球菌、人葡萄球菌和溶血葡萄球菌等臭汗症病原菌均具有抑制作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物,其特征在于,其保藏编号为CCTCC NO:M 2022108。
2.如权利要求1所述的植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备调节菌群、抗炎和/或抗过敏的产品中的应用。
3.如权利要求1所述的植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备促进表皮细胞修复、修复皮肤屏障、皮肤保湿、改善肌肤状况、治疗臭汗症、治疗痤疮和/或治疗鼻窦炎的产品中的应用。
4.如权利要求1所述的植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备下调细胞炎症因子表达、降低炎症因子释放、抑制致病菌生长、促进益生菌增殖和/或改变菌群比例的产品中的应用。
5.如权利要求1所述的植物乳杆菌(Lactobacillus plantarum)或其裂解物、提取物和/或代谢产物在制备降低细胞一氧化氮生成量,下调细胞IL-6、IL-8、COX-2和/或TRPV1的表达,提升由十二烷基硫酸钠损伤的细胞的存活率,上调FLG、IVL、OVOL1、LOR和/或GBA基因的表达,抑制流感嗜血杆菌生长,抑制铜绿假单胞菌生长,促进清酒乳杆菌增殖,抑制痤疮丙酸杆菌生长,抑制金黄色葡萄球菌生长,抑制人葡萄球菌生长和/或抑制溶血葡萄球菌生长的产品中的应用。
6.如权利要求2至5所述的应用,其特征在于,所述产品包括微生物制剂、食品、药物或化妆品。
7.微生物制剂,其特征在于,具有如权利要求1所述的植物乳杆菌(Lactobacillusplantarum)或其裂解物、提取物和/或代谢产物以及可接受的辅料和/或助剂。
8.食品,其特征在于,具有如权利要求1所述的植物乳杆菌(Lactobacillusplantarum)或其裂解物、提取物和/或代谢产物,和/或如权利要求7所述的微生物制剂以及可接受的辅料和/或助剂。
9.药物,其特征在于,具有如权利要求1所述的植物乳杆菌(Lactobacillusplantarum)或其裂解物、提取物和/或代谢产物,和/或如权利要求7所述的微生物制剂以及可接受的辅料和/或助剂。
10.化妆品,其特征在于,具有如权利要求1所述的植物乳杆菌(Lactobacillusplantarum)或其裂解物、提取物和/或代谢产物,和/或如权利要求7所述的微生物制剂以及可接受的辅料和/或助剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210484938.XA CN114703106A (zh) | 2022-05-06 | 2022-05-06 | 益生菌GforU-12及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210484938.XA CN114703106A (zh) | 2022-05-06 | 2022-05-06 | 益生菌GforU-12及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114703106A true CN114703106A (zh) | 2022-07-05 |
Family
ID=82177218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210484938.XA Withdrawn CN114703106A (zh) | 2022-05-06 | 2022-05-06 | 益生菌GforU-12及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114703106A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115948275A (zh) * | 2022-09-09 | 2023-04-11 | 青岛蔚蓝生物股份有限公司 | 一株植物乳植杆菌及其在预防和治疗呼吸道疾病中的应用 |
-
2022
- 2022-05-06 CN CN202210484938.XA patent/CN114703106A/zh not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115948275A (zh) * | 2022-09-09 | 2023-04-11 | 青岛蔚蓝生物股份有限公司 | 一株植物乳植杆菌及其在预防和治疗呼吸道疾病中的应用 |
CN115948275B (zh) * | 2022-09-09 | 2024-04-02 | 青岛蔚蓝生物股份有限公司 | 一株植物乳植杆菌及其在预防和治疗呼吸道疾病中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7117049B2 (ja) | 新規なキューティバクテリウムグラニュローサム菌株、該菌株またはその培養物を含むにきび予防または治療用組成物 | |
CN114806977B (zh) | 一株唾液乳杆菌及其在制备抗皮炎的产品中的应用 | |
CN114081901B (zh) | 一种益生菌组合物、制备方法及其应用 | |
CN114634899B (zh) | 发酵乳杆菌及其应用 | |
CN114369553A (zh) | 一株抗炎的表皮葡萄球菌 | |
CN114504599A (zh) | 副干酪乳杆菌et-22在抗衰老、提高先天免疫方面的新应用 | |
CN113604395A (zh) | 一株可发酵石斛且其发酵液可改善皮肤质量的植物乳杆菌 | |
CN115094011A (zh) | 一株加氏乳杆菌及其应用 | |
EP4245841A1 (en) | Novel use of bifidobacterium lactis bl-99 in fighting aging and improving innate immunity | |
CN114703106A (zh) | 益生菌GforU-12及应用 | |
CN114574408B (zh) | 益生菌seuneu-107及应用 | |
CN114645002A (zh) | 一种用于皮肤抗炎和治疗痤疮的副干酪乳杆菌及其应用 | |
CN114672442A (zh) | 益生菌ProfMIC-211及应用 | |
CN114891683A (zh) | 一株戊糖片球菌及其应用 | |
CN114657108A (zh) | 一种用于皮肤抗菌和屏障修复的副干酪乳杆菌及其应用 | |
CN114645001A (zh) | 一株副干酪乳杆菌及其在制备调节皮肤微生态系统的产品中的应用 | |
CN115491334A (zh) | 一株鼠李糖乳杆菌及其应用 | |
CN114717161A (zh) | 发酵乳杆菌及其应用 | |
CN114891699A (zh) | 调节菌群平衡的唾液乳杆菌 | |
CN114874945A (zh) | 一株短乳杆菌及其应用 | |
CN114561331B (zh) | 一株副干酪乳杆菌及其应用 | |
CN114990021A (zh) | 一株唾液乳杆菌及其在制备皮肤护理产品中的应用 | |
CN114645003A (zh) | 一株副干酪乳杆菌及其在制备皮肤抑菌和抗炎的产品中的应用 | |
CN115820476B (zh) | 一株德氏乳杆菌及其应用 | |
CN114621902A (zh) | 一株副干酪乳杆菌及其在制备防治皮肤病的产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220705 |
|
WW01 | Invention patent application withdrawn after publication |